Obicetrapib, a CETP inhibitor, raises ApoA-1 and generates tiny protein-rich HDL particles that can cross the blood-brain barrier. The BROADWAY trial showed movement in the right direction on phosphorylated tau, amyloid-40/42 ratios, and other Alzheimer's biomarkers — suggesting it may rescue dysfunctional APOE4 brain HDL.